NJ-LTIMINDTREE
4.3.2024 14:16:28 CET | Business Wire | Press release
Fosfor, a product division of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, at its Foton 2024 event, announced the launch of the Fosfor Decision Cloud (FDC). The FDC is a connected fabric that helps companies organize data to build automated, modular, trustworthy data transformation pipelines, build and deploy impactful AI applications, and harness the power of AI to make better business decisions, faster.
Currently companies need to create their own collection of disconnected point solutions to facilitate the transformation of data into business insights. The Decision Cloud represents the next step in the evolution of formerly disconnected data and AI investments into a modern decision stack that augments the data-to-decisions journey using three new innovations:
- Fosfor AI: The GenAI-powered assistant that helps with frequent tasks across the data-to-decisions journey such as constructing data pipelines, generating ML model code, constructing natural language prompts, and curating data stories. Fosfor AI radically increases productivity for virtually any user persona, thereby reducing time-to-insights and accelerating the realization of business outcomes.
- Fosfor Semantic: The knowledge graph used by all FDC capabilities to organize and maintain the integrity of data, define data relationships, and enable the application of advanced analytics to the data. Because Fosfor Semantic is used to facilitate everything from data integration to AI algorithm development to insight generation, it vastly accelerates all steps of the data-to-decisions journey.
- Fosfor UX: The design system through which all capabilities are accessed using consistent navigational elements and constructs, curated for specific personas based on their commonly used workflows and goals. Fosfor UX flattens the learning curve and simplifies collaboration across various personas, allowing all users to adapt more quickly to the FDC platform.
The FDC is supported by a robust partner ecosystem anchored by Snowflake, Fivetran, Amazon Web Services, Microsoft Azure, the Google Cloud Platform, and GoldenSource. Snowflake, the Data Cloud company, and Fivetran are FDC launch partners.
“The Decision Cloud marks a major milestone in the evolution of Fosfor and is a major breakthrough in the way businesses can develop and deploy AI to achieve business value,” said Debasis Satpathy, Chief Business Officer, Fosfor. “To elevate the impact of business outcomes, the Decision Cloud brings all the required capabilities onto a single platform, along with powerful insight tools, to support every persona involved in an accelerated data-to-decisions journey. We are excited about the impact the FDC is going to have on the business effectiveness of AI.”
"Organizations across industries continue to struggle with the fragmentation of applications and tools,” said Tarik Dwiek, Head of Technology Alliances, Snowflake. “With the Fosfor Decision Cloud seamlessly integrated into Snowflake, customers can now tap into a single experience to fully democratize their data and fuel their data-driven decision making.”
“Fivetran is pleased to be Fosfor’s launch partner for automated data movement,” said Scott Jones, Chief Revenue Officer, Fivetran. “Providing the foundational capability to integrate with virtually any data source to cost-effectively bring business data into cloud warehouses where the Decision Cloud can then transform it into insights and business value. Using our library of 400+ connectors, Decision Cloud users can focus on building outcome-targeted data products that accelerate their insights journey. We look forward to working together with Fosfor to define the modern decision stack and create transformational outcomes for our customers.”
Learn more about the Fosfor Decision Cloud at www.fosfor.com.
About Fosfor
The Fosfor Decision Cloud is a connected fabric that unifies and amplifies the value promised by the modern data ecosystem, which is made up of infrastructure, data, and application clouds. Fosfor enables organizations to effectively curate data, generate impactful insights, and formulate effective decisions to deliver the long-sought promise of data and AI: optimal business outcomes. Fosfor is part of LTIMindtree, a global technology consulting and digital solutions company. For more information, visit www.fosfor.com.
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 82,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304342757/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom